Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Elotuzumab and Daratumumab: A Single Center Experience

Fahmin Basher, MD PhD, Yonette Paul, MD MBBS, James E. Hoffman, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-142923

Published: 2020

Journal Articles

Is There an Unequal Benefit of Autologous Stem Cell Transplant in Different Cytogenetic Groups of High Risk Patients with Multiple Myeloma: The University of Miami Experience

Fahmin Basher, MD PhD, Sandra Sanchez, MD, Jonathan H. Schatz, MD, James E. Hoffman, MD, Lazaros J. Lekakis, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-143266

Published: 2020

Journal Articles

Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience

Yonette Paul, MD MBBS, Luis E. Aguirre, MD, Fahmin Basher, MD PhD, Feng Miao, MS, Tulay Koru-Sengul, PhD, James E. Hoffman, MD

Blood (2019) 134 (Supplement_1): 3131.

https://doi.org/10.1182/blood-2019-127247

Published: 2019

Journal Articles

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

Blood (2019) 134 (Supplement_1): 3140.

https://doi.org/10.1182/blood-2019-129038

Published: 2019

Journal Articles

Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics

Tania Jain, MD, Rafael Fonseca, MD, Ruqin Chen, MD, Raj Patel, MD, Prachi Jani, MD, Veronica Gonzalez De La Calle, MD, Zahara Meghji, James E. Hoffman, MD, Alvaro J. Alencar, MD, Kevin R Kelly, MD PhD, Vivek Roy, MD, Taimur Sher, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2017) 130 (Supplement 1): 864.

https://doi.org/10.1182/blood.V130.Suppl_1.864.864

Published: 2017

Journal Articles

Splenectomy in a Severe Case of Acquired Factor X Deficiency Secondary to Amyloidosis: Case Discussion and Review of the Literature

Terrence J Bradley, MD, Matthew P Salzberg, MD, George Nahas, DO, Basem Azab, MD, Alan Livingstone, MD, John J. Byrnes, MD, Thomas J. Harrington, MD, James E. Hoffman, MD

Blood (2017) 130 (Supplement 1): 4885.

https://doi.org/10.1182/blood.V130.Suppl_1.4885.4885

Published: 2017

Journal Articles

Phase II study of 90 y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma

Jesus C Fabregas, MD, James E. Hoffman, MD, Tulay Koru-Sengul, PhD, Miao Feng, Deborah Goodman, Aldo Serafini, MD, Peter J Hosein, MD, Alexandra Stefanovic, MD, Joseph D. Rosenblatt, MD, Izidore S. Lossos, MD

Blood (2014) 124 (21): 1762.

https://doi.org/10.1182/blood.V124.21.1762.1762

Published: 2014

Journal Articles

Patient With IgG Heavy Chain Disease Presents With Parathyroid Hormone-Related Peptide Mediated Hypercalcemia

Damien Hansra, MD, Victoria Sujoy, MD, Ikpatt Offiong, MD, Chris Wunsch, MD, James E. Hoffman, MD

Blood (2013) 122 (21): 5344.

https://doi.org/10.1182/blood.V122.21.5344.5344

Published: 2013

Journal Articles

Clinical Experience Of Lenalidomide Plus Low Dose Dexamethasone As First-Line Therapy For Multiple Myeloma At a Large County Hospital Caring For An Indigent Population

Yehuda E. Deutsch, MD, Daniel J Dammrich, MD, Jesus C Fabregas, MD, Agustin Pimentel, MD, Alexandra Stefanovic, MD, James E. Hoffman, MD

Blood (2013) 122 (21): 5399.

https://doi.org/10.1182/blood.V122.21.5399.5399

Published: 2013

Journal Articles

Urinary Excretion of Epinephrine and Dopamine Correlates with Efficiency of G-CSF Mobilized Stem Cells in Patients with AL Amyloidosis

Heather Landau, MD, Hani Hassoun, MD, James E. Hoffman, MD, Christina Bello, Elizabeth Hoover, Elyn Riedel, Paul S. Frenette, MD, FRCPC, Raymond L. Comenzo, MD

Blood (2011) 118 (21): 316.

https://doi.org/10.1182/blood.V118.21.316.316

Published: 2011

Journal Articles

Cyclin D1 Overexpression In Clonal Plasma Cells In Systemic AL Amyloidosis Is Associated with Differential Expression of Protein Quality Control Genes and Bias In Clonal Germline IgV L donor Gene Use

Ping Zhou, MD, PhD, Lakshmanan K Iyer, PhD, Hani Hassoun, MD, James E. Hoffman, MD, Heather Landau, MD, Raymond L. Comenzo, MD

Blood (2010) 116 (21): 4043.

https://doi.org/10.1182/blood.V116.21.4043.4043

Published: 2010

Journal Articles

Coincidental Gammopathies In Patients with Systemic Amyloidosis and Transthyretin Gene Mutations

James E. Hoffman, MD, Hani Hassoun, MD, Heather Landau, MD, Raymond L. Comenzo, MD

Blood (2010) 116 (21): 2948.

https://doi.org/10.1182/blood.V116.21.2948.2948

Published: 2010

Journal Articles

Elevated Cyclin D1 ( CCND1 ) Expression in the Plasma Cells of Patients with Systemic AL Amyloidosis at Diagnosis Is Associated with Higher Brain Natriuretic Peptide (BNP) Levels, Increased Plasma Cells and Significantly Poorer Survival.

Ping Zhou, PhD, James E Hoffman, MD, Hani Hassoun, MD, Heather Landau, MD, Raymond L Comenzo, MD

Blood (2009) 114 (22): 2815.

https://doi.org/10.1182/blood.V114.22.2815.2815

Published: 2009

Journal Articles

CD32B Expression Reflects Phenotypic and Functional Heterogeneity in Multiple Myeloma (MM)

Ping Zhou, MD, PhD, Adam M Boruchov, MD, James E. Hoffman, MD, Qianxing Mo, Adam Olshen, Evan Glasner, Ezio Bonvini, Scott Koenig, Ellen Drieghe, Martin Fleisher, PhD, Peter Maslak, MD, Hani Hassoun, MD, Adam D Cohen, MD, Heather Landau, MD, James W. Young, MD, Suresh C Jhanwar, PhD, Stephen D Nimer, MD, Raymond L Comenzo

Blood (2008) 112 (11): 842.

https://doi.org/10.1182/blood.V112.11.842.842

Published: 2008

Journal Articles

Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.

James E. Hoffman, MD, Hani Hassoun, MD, Heather Landau, MD, Elizabeth Hoover, Adam Cohen, MD, Stephen Nimer, MD, Raymond Comenzo, MD

Blood (2008) 112 (11): 3329.

https://doi.org/10.1182/blood.V112.11.3329.3329

Published: 2008

NARROW

Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Patients Receiving Sequential Elotuzumab and Daratumumab: A Single Center Experience

Is There an Unequal Benefit of Autologous Stem Cell Transplant in Different Cytogenetic Groups of High Risk Patients with Multiple Myeloma: The University of Miami Experience

Hypogammaglobulinemia and Its Implications in Patients Treated with Daratumumab: A Single Institution Experience

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics

Splenectomy in a Severe Case of Acquired Factor X Deficiency Secondary to Amyloidosis: Case Discussion and Review of the Literature

Phase II study of 90 y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma

Patient With IgG Heavy Chain Disease Presents With Parathyroid Hormone-Related Peptide Mediated Hypercalcemia

Clinical Experience Of Lenalidomide Plus Low Dose Dexamethasone As First-Line Therapy For Multiple Myeloma At a Large County Hospital Caring For An Indigent Population

Urinary Excretion of Epinephrine and Dopamine Correlates with Efficiency of G-CSF Mobilized Stem Cells in Patients with AL Amyloidosis

Cyclin D1 Overexpression In Clonal Plasma Cells In Systemic AL Amyloidosis Is Associated with Differential Expression of Protein Quality Control Genes and Bias In Clonal Germline IgV L donor Gene Use

Coincidental Gammopathies In Patients with Systemic Amyloidosis and Transthyretin Gene Mutations

Elevated Cyclin D1 ( CCND1 ) Expression in the Plasma Cells of Patients with Systemic AL Amyloidosis at Diagnosis Is Associated with Higher Brain Natriuretic Peptide (BNP) Levels, Increased Plasma Cells and Significantly Poorer Survival.

CD32B Expression Reflects Phenotypic and Functional Heterogeneity in Multiple Myeloma (MM)

Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only